Intranasal COVID Vaccine
COVID-19 Prevention
ResearchExploratory
Key Facts
About Virpax Pharmaceuticals
Virpax Pharmaceuticals is a pre-revenue, publicly traded company focused on developing non-addictive therapies for pain and central nervous system (CNS) disorders using its proprietary drug delivery platforms. Its core strategy involves leveraging cooperative research agreements with prestigious institutions like the NIH/NCATS and the U.S. Army to de-risk development and advance a pipeline led by Probudur, an ultra-long-acting local anesthetic. While the company has demonstrated promising preclinical data for its lead programs and is progressing towards clinical trials, it faces significant execution and financial risks common to early-stage biotechs, with its valuation reflecting its developmental stage.
View full company profileTherapeutic Areas
Other COVID-19 Prevention Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Vaccine Trials | DM Clinical Research | Not Specified |
| SARS-CoV-2 Vaccine | Epygen Biotech | Not Disclosed |
| COVAXIN | Bharat Biotech | Commercial |
| iNCOVACC | Bharat Biotech | Commercial |
| IRT Platform (e.g., COVID-19) | Biological Mimetics | Research/Pre-clinical |
| Replicon RNA COVID-19 Vaccine | BIKEN Group | Preclinical/Development |
| Convidecia Air® (XBB.1.5 Variant) | CanSino Biologics | Approved |
| COVID-19 Vaccine | Recbio Technology | Not specified |
| COMIRNATY® (BNT162b2) | Fosun Pharma | Approved |
| BBIBP-CorV | Sinopharm | Approved |
| Recombinant Protein COVID-19 Vaccine | Sinopharm | Approved |
| COVID-19 mRNA Vaccine (SYS6006) | CSPC Innovation Pharmaceutical | Marketed |